학술논문

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)
Document Type
Abstract
Source
In Transplantation and Cellular Therapy February 2024 30(2) Supplement:S384-S385
Subject
Language
ISSN
2666-6367